Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease by Kastenbauer, U et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH June 18, 2009
Abstract
Objectives: There is only little data on immune recon-
stitution in antiretroviral na￯ve AIDS-patients with
toxoplasmosis. The observation of several cases with
reduced increase of CD4-cells upon start of antiretro-
viral treatment (ART) prompted us to investigate the
topic using the ClinSurv cohort.
Methods: 17 German HIV treatment centers con-
tribute to ClinSurv, a multicentre observational cohort
under the auspices of the Robert Koch Institute. We
retrospectively selected all antiretroviral-na￯ve patients
with toxoplasmic encephalitis (TE) and - as compara-
tor group - with pneumocystosis (PCP) between Janu-
ary 1999 and December 2005.
Results: A total of 257 patients were included in the
analysis, 61 with TE and 196 with PCP. Demographic
baseline data showed differences with regard to gen-
der, transmission group, and baseline CD4+ counts
(60.9 vs. 44.7/ﾵl, p = 0.022). After ART-initiation the
increase in CD4+ lymphocytes was lower in the TE-
versus the PCP-group in the first, second and fourth
three-month-period (74.4 vs. 120.3/ﾵl, p = 0.006; 96.6
vs. 136.2/ﾵl, p = 0.021; 156.5 vs. 211.5/ﾵl, p = 0.013).
Viral load (VL) was higher in the PCP-group at base-
line (4.46 log10cop/ml vs. 5.00 log10cop/ml, p =
0.008), while virological success of ART was equal.
Conclusions: Our data show for the first time that the
average CD4+ T-cell increase of patients with toxo-
plasmosis is impaired compared to PCP-patients. Most
clinicians would not be prepared to discontinue fol-
low-up TE-therapy unless CD4+ counts of 200/ﾵl are
reached. Explanation for our finding might be the
myelosuppressive side effect of pyrimethamine, possi-
ble interactions of toxoplasmosis therapy with ART,
or an unknown direct biological influence of toxoplas-
mosis on immune restoration.
Key words: Antiretroviral therapy, highly active; CD4+
lymphocyte count; HIV; pneumocystis jiroveci pneu-
monia; toxoplasmic encephalitis
List of Abbreviations: AIDS = Acquired immune de-
ficiency syndrome, ART = Antiretroviral therapy,
HPC = Patients from countries of high HIV-preva-
lence, M1, M2… = Month 1, month 2…, MSM =
Men who have sex with men, OI = Opportunistic in-
fection, PCP = Pneumocystis pneumonia, Q1, Q2…
= Quarter 1, quarter 2…, TE = Toxoplasmic en-
cephalitis, VL = Viral load
INTRODUCTION
Although the development of efficient antiretroviral
treatment options has changed the face of the AIDS
epidemic in industrialized countries, opportunistic in-
fections like toxoplasmic encephalitis or pneumocystis
pneumonia still present a considerable challenge [1-3].
Especially in patients in a late stage of HIV infection,
symptoms of AIDS-defining diseases are a common
reason for first hospital admission [4-6]. While de-
tailed treatment guidelines exist for most opportunis-
tic infections, the situation regarding toxoplasmosis is
more difficult. Especially the question when to initiate
antiretroviral treatment in order to avoid immune re-
constitution problems, and when to stop the anti-in-
fective therapy remains open in most guideline reviews
[7]. One reason for this may be the significantly lower
incidence of toxoplasmic encephalitis in the USA
compared with European countries [8-10]. Only scarce
data about immunological and virological response to
highly active antiretroviral therapy initiated in patients
treated for toxoplasmosis is to be found in the litera-
ture. Observation of such patients in the clinical set-
ting led to the hypothesis of an impaired CD4+ lym-
phocyte response to ART.
METHODS
To further investigate this hypothesis we used the
database of the “ClinSurv HIV” cohort, a multicentre
cohort of 17 German HIV clinics led by the Robert
Koch Institute in Berlin. The data reported biannually
includes clinical and laboratory parameters, patient de-
mographics, transmission route, date of HIV-diagno-
sis, clinical stage, AIDS related or AIDS defining dis-
eases, antiretroviral treatment and date of death. We
retrospectively searched this database for patients who
matched the following criteria: Diagnosis of either
toxoplasmic encephalitis or pneumocystis pneumonia
in the period between January 1999 and December
2005; ART-na￯ve; initiation of ART in the 2 months
following the OI-diagnosis; sufficient documentation
of ART-regimen, viral load and CD4+ T-cell count
(defined by at least three measurements of each labo-
ratory parameter) in the 12 months following ART-ini-
tiation; and a CD4+ lymphocyte count below 200/ﾵl at
baseline. PCP-cases were chosen as a control group
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sufficient number of patients with a comparably im-
paired immunologic status. Diagnosis of PCP was es-
tablished by detection of Pneumocystis jiroveci in the
broncho-alveolar lavage. Toxoplasmosis was diagnosed
by brain imaging, clinical signs, serology and response
to anti-Toxoplasma treatment according to the Euro-
pean AIDS case definition [11] and the CDC “1993
Revised Classification System for HIV Infection and
Expanded Surveillance Case Definition for AIDS
Among Adolescents and Adults“ [12].
The two groups were compared regarding their de-
mographic characteristics, baseline viral load and
CD4+/CD8+ T-cell count, as well as virological and
immunological response in the first 12 months of
ART. Every laboratory test performed in this period
was assigned to a one-month-window (M1, M2, M3
… and M12) and in a second step, because of the
high amount of missing values, to a three-month-win-
dow (quarter Q1, Q2, Q3 and Q4) starting from the
date of ART-initiation. For windows containing more
than one value an arithmetic mean was calculated. If a
window contained viral-load values both below detec-
tion limit (<50 copies/ml) and above, only the latter
were taken into account. Virological response to ART
was compared using cross tables and Chi-squared test
for percentage of patients with a VL below the limit
of detection after 6 and 12 months of ART and per-
forming Kaplan-Meier survival analysis for time to vi-
ral load suppression (defined by two consecutive VL-
measurements <50 cop/ml). Mean values of absolute
CD4+ lymphocyte count, total lymphocytes and delta-
CD4 (increase in CD4+ T-cells in comparison to base-
line) were compared by T-test. In order to look at a
more clinically relevant parameter for a positive anti-
retroviral treatment outcome, immunological re-
sponse was defined as reaching a CD4+ lymphocyte
count of 200/ﾵl or higher and compared performing
a Kaplan-Meier analysis regarding time to this event.
A uni- and multivariate analysis of factors with possi-
ble influence on the probability of immunological re-
sponse in Q2 was performed. Therefore the odds ra-
tios as estimators of the relative risk to reach im-
munological response were calculated using cross ta-
bles (univariate) and logistic regression analysis (multi-
variate). The multivariate analysis adjusted for age and
sex and included all factors with a p<0.2 in the uni-
variate analysis.
RESULTS
BASELINE CHARACTERISTICS
A total of 257 patients within the CLINSURV data set
of 17,521 patients enrolled in the cohort at time of
data collection met the selection criteria: 61 with diag-
nosis of toxoplasmosis, and 196 with diagnosis of
pneumocystis pneumonia (see Table 1 for details). No
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Table 1. Overview of baseline characteristics in the compared groups; SD = standard deviation, MSM = men who have sex with
men, HPC = patients from countries of high HIV prevalence, ART = antiretroviral therapy, IQR = interquartile range, NNRTI =
antiretroviral regimen based on NNRTI, PI = antiretroviral regimen based on PI, NRTI or NNRTI/PI = antiretroviral regimen ei-
ther consisting of NRTI only or including NNRTI and PI; p-values calculated by T-test, Chi-squared or Mann-Whitney-U test.
TE (n = 61) PCP (n = 196)
n / mean % / SD n / mean % / SD p
Age 40.8 8.4 41.0 10.5 0.876
Female 16 26.2% 28 14.3% 0.031
Migrant 13 21.3% 41 20.9% 0.948
Transmission risk
MSM 25 41.0% 114 58.2% 0.013
HPC 11 18.0% 14 7.1%
Other 25 41.0% 68 34.7%
ART initiation date Apr 02 34 months Sep 01 35 months 0.631
(median) (IQR) (median) (IQR)
Firstline-ART
NNRTI 11 18.0% 34 17.3% 0.069
PI 45 73.8% 119 60.7%
NNRTI/PI 3 4.9% 37 18.9%
NRTI 2 3.3% 6 3.1%
Baseline values
CD4 /ﾵl 60.9 44.2 44.7 42.1 0.022
CD8/ﾵl 637.2 301.2 726.4 492.3 0.222
%CD4 6.8 4.3 4.8 3.9 0.013
%CD8 67.0 13.3 65.2 15.9 0.565
VL (log10Kop/ml) 4.46 1.20 5.00 1.02 0.008
Lymphocytes/ﾵl 981.8 544.1 1,056.0 887.39 0.635
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of patients with migration background, date of ART-
initiation, baseline CD8-cell-count and total lympho-
cyte count.
The percentage of female patients in the TE-group
was significantly higher than in the PCP-group. The
distribution of patients over the different HIV trans-
mission risk categories also diverged significantly, es-
pecially with regards to the proportion of men who
have sex with men (MSM) and patients from countries
of high HIV-prevalence (HPC). In both groups, ART-
regimens based on a boosted protease inhibitor (PI)
were chosen as first line antiretroviral treatment in
more than 60% of the cases, followed in frequency by
non-nucleoside reverse transcriptase inhibitor (NNR-
TI) based regimens. An unusually high amount of
PCP-patients was initially treated with a combination
including both PI and NNRTI. Almost 50% of the
TE-patients started antiretroviral treatment within a
month after OI-diagnosis, while in over 60% of the
PCP-group ART-initiation was delayed until the 1st
month after diagnosis.
The TE-patients in this analysis showed a higher
absolute and relative CD4-cell count at baseline com-
pared to the PCP-group. At the same time the baseline
viral load was significantly lower in the TE-group.
VIROLOGICAL AND IMMUNOLOGICAL RESPONSE
Virologic response to ART was comparable in both
groups; not only regarding the percentage of patients
with viral load below detection limit after 6 (68.4% vs.
77.5%, p = 0.279) and 12 months (87.5% vs. 77.5%, p
= 0.369), but also comparing both groups in regards
to “time to the second consecutive HIV-PCR with a
result of <50 cop/ml”. The Kaplan-Meier analysis
showed a median time to this event of 8 months in
both groups (p = 0.919, log-rank test).
Absolute CD4+ lymphocyte count, delta-CD4, and
total lymphocyte count were numerically lower in the
TE-group in all 4 quarters. In Q1, TE-patients showed
a significantly lower absolute CD4+ lymphocyte count
(129.1/ﾵl vs. 163.6/ﾵl, p = 0.043) as well as a reduced
CD4+ T-cell increase (+74.4/ﾵl vs. +120.3/ﾵl,
p = 0.006) and less total lymphocytes (1,205.3/ﾵl
vs. 1,669.4/ﾵl, p<0.001). In the 2nd and 4th quarter,
only delta-CD4 and total lymphocyte count re-
mained significantly impaired in the TE-group (see
Fig. 1).
The percentage of TE-patients reaching an average
CD4+ lymphocyte count of at least 200/ﾵl was well
below that of PCP-patients in Q1 and Q2, while in the
second half of the observation period this difference
seems to disappear (see Fig. 2). A Kaplan-Meier analy-
sis comparing time to the event “first absolute CD4+
lymphocyte count ≥200/ﾵl” showed a non-significant
advantage for the PCP-group with a median time to
event of 8 months (vs. 10 months in the TE-group, p
= 0.269, log-rank test).
To identify other factors possibly related with re-
duced immunological response, uni- and multivariate
analyses were performed. Besides TE (vs. PCP) they
included the factors age, gender, MSM, HPC, PI- and
NNRTI-based first-line ART-regimen, date of ART-
initiation, baseline viral load and baseline CD4+ T-cell
count. Of all these factors only diagnosis of toxoplas-
mosis and a baseline CD4+ lymphocyte count below
50 cells/ﾵl were associated with a significantly lower
probability of reaching the defined CD4+ goal of
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Fig. 1. Course of mean absolute CD4-cell count, delta-CD4
and total lymphocytes through the four quarters of the obser-
vation period; TE patients show reduced values in all three
parameters. * = p < 0.05
Fig. 2. Lower proportion of TE patients with immunologic
response, defined as average CD4-cell count ≥200/ﾵl, in Q1
(19.3% vs. 29.3%, p = 0.135) and Q2 (20.3% vs. 34.1%, p =
0.047, calculated by Chi-squared test).
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the multivariate analysis adjusting for age, sex and date
of ART-initiation (as the only factor with a p<0.2 in
the univariate analysis) (see Table 2).
DISCUSSION
Our analysis shows that immunological response to
ART initiated in patients with diagnosis of toxoplas-
mosis is impaired when compared to patients with
PCP. This difference comprises lower absolute CD4+
lymphocyte counts and delta-CD4, as well as a signifi-
cantly reduced probability of reaching ≥200 CD4+ T-
cells/ﾵl in the second quarter of the observed first
year under ART. This negative effect gets weaker (and
disappears) in the second half-year period following
the start of ART. The observed lower CD4+ lympho-
cyte count seems to derive mainly from a reduced total
lymphocyte count in the TE-group. A plausible expla-
nation could be the known myelosuppressive side ef-
fects of anti-infective agents used as recommended
standard treatment for toxoplasmosis (pyrimethamine)
[13-15]. The substitution of folic acid routinely pro-
vided during TE-therapy with pyrimethamine only
partially prevents this side effect. The standard PCP
treatment with cotrimoxazole can impair the bone
marrow as well, but it has a smaller myelosuppressive
potency than pyrimethamine, furthermore the sug-
gested duration of PCP-therapy is shorter than for TE
[7, 16].
If this conclusion will prove correct in further stud-
ies, guidelines suggesting a solely CD4-cell guided du-
ration of maintenance therapy would have to be re-
viewed, in order to avoid a sort of “vicious circle”:
Low CD4+ T-cell count leads to ongoing
pyrimethamine-treatment leads to low CD4+ T-cell
count etc. D’Egidio et al. have already showed that
with sustained viral load suppression the termination
of secondary PCP-prophylaxis should be possible also
for patients with a CD4-cell count below 200/ﾵl [17].
To evaluate a similar concept for toxoplasmic en-
cephalitis further research is necessary. Another con-
sequence should be an intensified search for alterna-
tive anti-toxoplasmosis drugs with less hematotoxic
side effects [18-21], as well as strategies to directly en-
hance CD4+ lymphocyte increase, always considering
the possibility of multiple drug interactions in this set-
ting of extensive treatment [22, 23].
A less probable reason for the observed difference
would be a direct interaction of the opportunistic in-
fection with the immune system, for example by sup-
pressing myelopoiesis, as it has been shown for gener-
alized infection with Mycobacterium avium complex
(MAC) [25-27]. A similar myelosuppressive effect
caused by Toxoplasma has been demonstrated in the
acute infection in mice. Finally, the use of corticos-
teroids in initial PCP-therapy could be proposed as a
reason for higher CD4-cell counts. There have been
reports from small HIV-patient populations showing
an increase in CD4-cells when patients were treated
with prednisolone [29, 30]. As exact data about steroid
use in both groups is lacking, we did not include this
factor in our analysis.
LIMITATIONS
Due to the retrospective nature of the ClinSurv co-
hort, the authors could not confirm each diagnosis of
TE / PCP by assessing the diagnostic procedures that
were applied. Diagnosis was performed by the clini-
cians at the treatment centers who were asked to re-
port only cases of confirmed TE / PCP diagnosis, es-
tablished according to the above mentioned guidelines.
Especially for TE a bias due to incorrectly diagnosed
OI cannot be ruled out.
As mentioned above the compared groups signifi-
cantly diverged along the following baseline character-
istics: gender, HIV-transmission group, first line ART-
regimen, time from OI diagnosis to ART-initiation,
baseline CD4+ lymphocyte count and viral load. These
differences are difficult to explain and may mainly re-
sult from the low number of cases or from a bias due
to incorrectly diagnosed OI. A reason for the higher
percentage of patients from HPC in the TE-group
could be a higher seroprevalence of Toxoplasma gondii
in hot and humid regions and countries with lower hy-
giene standards [9]. An explanation for the uncommon
choice of first-line ART in the PCP group (18.9 %
PI/NNRTI containing regimen) may be a higher base-
line viral load and lower baseline CD4+ lymphocyte
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Table 2. Uni- and multivariate analysis showing significant influence on immunologic response, here defined as average CD4-
cell count ≥200/ﾵl in Q2, only for the factors TE and baseline CD4 <50/ﾵl.
Univariate analysis Multivariate Analysis
Factor odds ratio p odds ratio p
TE (vs. PCP) 0.576 0.047 0.403 0.033
Age ≥40 (vs. <40) 1.308 0.067 1.582 0.171
Female gender (vs. male) 0.827 0.555 0.931 0.872
MSM (vs. other transmission risk) 1.141 0.29
HPC (vs. other transmission risk) 0.797 0.614
PI-based first line ART (vs. other) 0.961 0.708
NNRTI-based first line ART (vs. other) 0.978 0.941
ART-initiation before 11/01 (vs. 11/01 and later) 0.821 0.176 0.926 0.816
Baseline VL >5log10 (vs. ≤ 5log10) 1.148 0.318
Baseline CD4 <50/ﾵl (vs. ≥50/ﾵl) 0.603 < 0.001 0.281 < 0.001
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4.82cop/ml, p = 0.007, CD4+ 36.9 vs. 50.8/ﾵl, p =
0.075, compared to all patients with different first-line
ART) as rationale for a more intense ART-regimen.
The different time to ART-initiation may have its
cause in the treatment guidelines: Waiting until the ini-
tial anti-infective treatment shows clinical response is
suggested for several OI including PCP, while for tox-
oplasmosis clear indications for the ideal time to start
with ART are missing in the guidelines [7, 31].
In a sensitivity analysis adjusting for all these fac-
tors, the above mentioned influence of a low CD4+ T-
cell count (<50/ﾵl) on the probability of reaching
≥200 CD4+/ﾵl proved highly significant, “TE” only
marginally missed significance-level in this analysis (p
= 0.059). Therefore, the risk of a bias caused by these
differences should be negligible.
Regarding the differences in baseline VL and CD4-
cell count, there is some evidence that a lower viral load
and/or a lower CD4-cell count before starting ART is
associated with a higher risk of discordant immunolog-
ic and virologic response to treatment [24]. This leaves
us with the dilemma that, on the one hand, the lower
baseline viral load in the TE group could have led to
the impaired CD4-cell increase in this group, while on
the other hand the higher baseline CD4-cell count in
the TE patients should have had the opposite effect.
Data collection for the ClinSurv cohort consists of
a preselected catalogue of parameters. This catalogue
does not necessarily take into account all information
which could have been of interest for some of the
questions this retrospective analysis brought up. Not
recorded were data like the kind and duration of anti-
infective treatment or ART adherence. Further, as
ClinSurv is an observational cohort, data collection is
not connected to predefined follow-up time points.
Therefore laboratory parameters like CD4+ lympho-
cyte count or viral load are measured in very divergent
intervals. The only inclusion criteria regarding quantity
of laboratory data for this analysis were a minimum of
three CD4+ T-cell count and viral load measurements
performed during the observation period. Conse-
quently some of the patients contribute information
to the analysis only for part of the year observed. Fur-
thermore calculating averages for quarters with more
than one lab value could have led to a bias by overrat-
ing single values. Excluding patients with missing val-
ues for one or more of the four quarters would have
led to a substantial loss of information. On the other
hand the minimum quantity of measurements could
have led to a selection bias towards patients with fa-
vorable courses of their diseases, taking into account
that none of the selected patients died during the one-
year follow-up period.
CONCLUSION
Toxoplasma encephalitis seems to be associated with
an impaired immunological response to ART com-
pared to patients with pneumocystis pneumonia. This
regards mainly the first months after ART-initiation
and may be caused by the myelosuppressive side ef-
fects of anti-toxoplasmosis drugs. Further investiga-
tions about this effect including direct biological influ-
ence of toxoplasmosis on immune restoration and
drug interactions between ART and anti-infective
treatment are of great interest. The search for new
drugs against Toxoplasma gondii should be intensified
as well. With respect to clinical management, other
hematotoxic drugs should be avoided in this setting.
Guidelines regarding time of initiation and duration of
anti-toxoplasmosis treatment should be critically re-
viewed, especially to avoid the “vicious circle” of deci-
sions guided solely by CD4-cell count.
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